INSP Stock Recent News

Today, we take a deeper look at Inspire Medical Systems, Inc., a medical device manufacturer focused on solutions for obstructive sleep apnea. Despite stellar revenue growth and a rock-solid balance sheet, the stock has fallen more than 50% from recent highs this summer. Is it time to buy the dip in Inspire Medical Systems shares?  An analysis follows in the paragraphs below.

MINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2023 after the close of trading on Tuesday, November 7. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

MINNEAPOLIS, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 2023 Healthcare Conference on Wednesday, September 6, 2023.

Inspire Medical Systems has performed well in 2023 with its hyperglossal nerve stimulation design for sleep apnea sufferers. The company plans to release a version without a sensor lead in 2024, making the procedure even easier for physicians. Inspire is focused on creating high-quality software to improve the user experience and compete with cumbersome masks.

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the second quarter.

Inspire Medical Systems, Inc. (NYSE:INSP ) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants John Block - Stifel Robbie Marcus - JPMorgan Travis Steed - Bank of America Adam Maeder - Piper Sandler Richard Newitter - Truist Securities Lei Huang - Wells Fargo Anthony Petrone - Mizuho Americas David Rescott - Baird Matthew Mishan - KeyBanc Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. My name is Dilem [ph], and I'll be your conference operator today.

While the top- and bottom-line numbers for Inspire (INSP) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Inspire Medical Systems (INSP) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.53 per share a year ago.

Inspire Medical Systems has reported a significant 84% rise in Q1 2023 revenue, reaching $127.9 million, driven by its innovative treatments for Obstructive Sleep Apnea. The company has received FDA clearance for expanded indications of its Inspire therapy, broadening the range of patients who can access the treatment. Despite facing competition and adoption challenges, Inspire's financial strength, innovative product pipeline, and recent successes position it as a compelling investment opportunity in the OSA market.